Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
Langerhans’ cell histiocytosis of the spine in children with soft tissue extension and chemotherapy
✍ Scribed by Xin-Sheng Peng; Tao Pan; Li-Yan Chen; Gang Huang; Jin Wang
- Publisher
- Springer
- Year
- 2008
- Tongue
- English
- Weight
- 276 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0341-2695
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Langerhans cell histiocytosis (LCH) has Society. Adoption of a uniform clinical/labopresented problems in diagnosis and in ratory approach to these children, coupled treatment.Thedefinitivediagnosis isapatho-with agreed-upon steps to the pathologic logic one. To advance thorough and uni-identificati
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
## Abstract Fifty‐two pediatric patients with Langerhans cell histiocytosis (LCH) were diagnosed at the Emma Kinderziekenhuis (EKZ) in Amsterdam over a 20‐year period. Eight patients with multiorgan involvement with organ dysfunction and ten patients with multiorgan involvement without organ dysfun